Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Quimioterapia con o sin radiación o cirugía en el tratamiento de participantes con cáncer de esófago o gástrico oligometastásico

5 de octubre de 2026 actualizado por: M.D. Anderson Cancer Center

Un ensayo aleatorizado que compara la quimiorradiación local temprana +/- cirugía versus la terapia sistémica para pacientes con cáncer de esófago o gástrico con oligometástasis

This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic). Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Surgery, such as complete surgical resection, may stop the spread of tumor cells by surgically removing organs or tumors. Giving chemotherapy with radiation or surgery may work better than chemotherapy alone in treating participants with oligometastatic esophageal or gastric cancer.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVES:

I. To evaluate whether esophageal or gastric patients with oligometastatic cancer without disease progression after first line chemotherapy therapy will demonstrate improved overall survival (OS) with early local therapy (concurrent chemotherapy/radiation and surgery).

SECONDARY OBJECTIVES:

I. Assess the relationships between progression-free survival and overall survival between both treatment arms.

II. Report local control, loco-regional control. III. Report time to progression of distant metastases. IV. Report toxicity.

OUTLINE:

Participants receive induction chemotherapy for a minimum of 6 cycles and a maximum of 8 cycles in the absence of disease progression or unacceptable toxicity. Participants are then randomized to 1 of 2 groups.

GROUP I (MAINTENANCE CHEMOTHERAPY): Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.

GROUP II (LOCAL THERAPY): Participants receive fluorouracil and capecitabine and undergo radiation therapy (RT) per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.

After completion of study treatment, participants are followed up at 4-8 weeks, 2-3 months, every 3-6 months for up to 3 years, and then every 6-12 months thereafter.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

100

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • M D Anderson Cancer Center
        • Contacto:
          • Quynh-Nhu Nguyen
          • Número de teléfono: 713-563-2300
        • Investigador principal:
          • Quynh-Nhu Nguyen

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 79 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • The patient has a pathologic diagnosis of tumor biopsy or FNA of esophageal or gastric cancer of adenocarcinoma histology

  • The patient is staged with EGD and PET/CT scan.

  • The patient has three or less observable metastatic lesions. Patients may have three or less radiographically visible metastatic lesions at diagnosis or if have regressed to three or less metastatic lesions after induction chemotherapy at time of randomization. The patient must have pathologic confirmation and or radiologically visible disease. For esophageal tumors, the maximal dimension of the primary tumor may not provide reproducible measurements for RECIST and may not be visible on CT or PET/CT at diagnosis or after induction chemotherapy. Accordingly, patients are eligible regardless of the imaging measurements of the primary tumor. Additionally, in patients with non-measurable metastases, patients are eligible if there is pathology confirming metastases from a distant site. However, biopsy of a metastatic site is not required if there are visible metastases on imaging (such as ultrasound, diagnostic CT , EUS, PET/CT).

    • The patient has three or less observable metastatic lesions by diagnostic scans (CT scan, PET/CT, eEndoscopic ultrasound, MRI, or bone scan). Metastatic lesions include distant M1 lymph node group; which will be counted as one site (M1 metastatic lymph nodes to include cervical, mediastinal, gastric, retroperitoneal lymph nodes will be counted as one lesion).
    • Osseous metastases or visceral metastases will each count as one metastatic site.
    • Each CNS metastases will count as one metastatic site.
    • Satellite lesions in the primary esophageal malignancy such as skipped esophageal primaries are not considered metastatic sites. Symptomatic metastatic sites can be treated locally prior to randomization or by palliative radiation.
    • Symptomatic metastatic sites may be treated with radiation or surgery prior to enrollment.
  • Patient ECOG of 0-2, with life expectancy of at least 6 months

  • Patients age >18 yrs old but <80 yrs old and signed informed consent

  • Women of child-bearing age must have pregnancy test at time of enrollment, agree to use of adequate contraception (birth control hormone or barrier method) for the duration of the study and for six months after discontinuation of systemic agents.

Exclusion Criteria:

  • Patients with prior chemotherapy or radiation therapy for their diagnosis of esophageal or gastric cancer. Patients with prior radiation therapy to same site for another diagnosis of cancer. Note: Patients may receive palliative radiation to their symptomatic sites of metastases but not definitive local therapy to esophageal or gastric primary prior to randomization. All patients may be enrolled on protocol then start systemic therapy; if they do not have evidence of disease progression at re-staging following initial therapy, they may be randomized.

  • Patients with fistula documented radiographically or by EDG/EUS, EBUS.

  • Patients with life expectancy less than 6 months, ECOG >3

  • Female patients who are pregnant confirmed by bHCG lab test.

  • Patient has history of uncontrolled angina, congestive heart failure or recent MI within 6 months.

  • Nursing females

  • Patients in poor nutritional state

  • Patients with:

    • Severely depressed bone marrow function
    • Potentially serious infections
    • Known hypersensitivity to 5-fluorouracil
    • Known or suspected to have a dihydropyrimidine dehydrogenase deficiency (as these patients are at a greater risk of experiencing symptoms of toxicity)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Group I (maintenance chemotherapy)

Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Otros nombres:
  • Xeloda
  • Ro 09-1978/000

Receive induction chemotherapy

Otros nombres:
  • Quimioterapia
  • Quimioterapia (NOS)
  • Quimioterapia, Cáncer, General

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Otros nombres:
  • 5-FU
  • 5-fluracilo
  • Fluracilo
  • 5-fluoro-2,4(1H, 3H)-pirimidindiona
  • 5-fluorouracilo
  • AccuSite
  • Carac
  • Fluorouracilo
  • Fluoracilo
  • Flurablastina
  • Fluracedil
  • Fluril
  • Fluroblastina
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757
Experimental: Group II (local therapy)

Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.

Undergo surgery

Undergo RT

Otros nombres:
  • Radioterapia del cáncer
  • Irradiar
  • Irradiado
  • Radiación
  • Radioterapéutica
  • RT
  • Terapia, Radiación
  • irradiación
  • RADIOTERAPIA

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Otros nombres:
  • Xeloda
  • Ro 09-1978/000

Receive induction chemotherapy

Otros nombres:
  • Quimioterapia
  • Quimioterapia (NOS)
  • Quimioterapia, Cáncer, General

Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.

Otros nombres:
  • 5-FU
  • 5-fluracilo
  • Fluracilo
  • 5-fluoro-2,4(1H, 3H)-pirimidindiona
  • 5-fluorouracilo
  • AccuSite
  • Carac
  • Fluorouracilo
  • Fluoracilo
  • Flurablastina
  • Fluracedil
  • Fluril
  • Fluroblastina
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall survival (OS)
Periodo de tiempo: Up to 6 years

OS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm.

Up to 6 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Local progression-free survival (PFS)
Periodo de tiempo: Up to 6 years

PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm.

Up to 6 years
Distant PFS
Periodo de tiempo: Up to 6 years

PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm.

Up to 6 years
Incidence of adverse events
Periodo de tiempo: Up to 6 years

Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Up to 6 years
Time to local or regional disease recurrence
Periodo de tiempo: Up to 6 years

To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates.

Up to 6 years

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to local disease recurrence
Periodo de tiempo: Up to 6 years

To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates.

Up to 6 years
Time to disease progression
Periodo de tiempo: Up to 6 years

To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates.

Up to 6 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Quynh-Nhu Nguyen, M.D. Anderson Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de febrero de 2018

Finalización primaria (Estimado)

31 de diciembre de 2026

Finalización del estudio (Estimado)

31 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

18 de mayo de 2017

Primero enviado que cumplió con los criterios de control de calidad

18 de mayo de 2017

Publicado por primera vez (Actual)

19 de mayo de 2017

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir